The Dental and Pharmaceutical Benefits Agency, TLV
Per Andersson is an experienced IT technician currently employed at The Dental and Pharmaceutical Benefits Agency (TLV) since March 2017. In this role, Per Andersson is responsible for managing the agency's hardware, including computers, mobile devices, printers, and conference equipment, as well as overseeing alarm and access systems. Prior experience includes working as a support specialist at Axians SE from April 2011 to March 2017, providing IT support for end users as part of the 2nd line support team. Earlier in Per Andersson's career, a position as a support technician at Datametrix from 2001 to April 2011 involved resolving urgent issues for both internal and external customers. In addition, Per Andersson worked at Pitney Bowes Svenska AB from 1983 to 2001 as a support technician and team leader, where responsibilities included assigning service tasks to technicians.
This person is not in the org chart
This person is not in any teams
The Dental and Pharmaceutical Benefits Agency, TLV
The Dental and Pharmaceutical Benefits Agency, TLV, is a central government agency whose remit is to determine whether a pharmaceutical product or dental care procedure shall be subsidized by the state. Our duty is to examine which medicines, medical devices and dental care treatments will be subsidised by society. We also contribute to quality service and accessibility of pharmacies. Our duty is to examine which medicines, medical devices and dental care treatments will be subsidised by society.In addition to examining new medicines, we also work systematically to evaluate the medicines included in the high-cost threshold to determine whether their reimbursement should be maintained or restricted. On the pharmacy market our remit is to create the conditions for quality service and accessibility at pharmacies. We do this partly through the generic substitution system, the retail margin for pharmacies and by monitoring the pharmacy market. Furthermore, we decide how much a medicine or a medical device in the high-cost threshold should cost. And, we determine what margin pharmacies should use when selling products, meaning the difference between the wholesale and retail prices. We determine the pricing for new dosage forms, strengths and packaging and examine whether they should be included in the high-cost threshold.